Use of human intravenous immunoglobulins in the treatment of severe COVID-19 – a multicentre, pseudonymised, retrospective scientific data collection

Use of human intravenous immunoglobulins in the treatment of severe COVID-19 – a multicentre, pseudonymised, retrospective scientific data collection - Human immunoglobulin in COVID-19

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025794

Enrollment

300

Registered

2021-07-06

Start date

2021-07-11

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe COVID-19 J80.0

Interventions

Group 1: Treatment with IgM-enriched immunoglobulins

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: ? Age =18 years ? Confirmed infection with SARS-CoV-2 ? Intensive-care treatment in the period between March 2020 and April 2021 ? A severe course of COVID-19 disease with confirmation of (at least) one of the following symptoms: o Shortness of breath, respiratory rate =30 breaths/minute o Oxygen saturation = 93% at rest under ambient air or mandatory oxygen o Oxygenation index = 300 mmHg (1 mmHg = 0.133 kPa)

Exclusion criteria

Exclusion criteria: Age < 18 years

Design outcomes

Primary

Measure	Time frame
30-day mortality	—

Secondary

Measure	Time frame
- Duration of stay in the intensive-care unit - Duration of stay in hospital - Mortality in the intensive-care unit - Organ support free days (ventilation and vasopressor) - Dialysis-free days	—

Countries

Austria, Germany, Italy

Contacts

Public ContactTim Rahmel

Universitätsklinikum Knappschaftskrankenhaus Bochum Klinik für Anästhesiologie, Intensivmedizin und Schmerzmedizin

Tim.Rahmel@ruhr-uni-bochum.de00492342993001

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 17, 2026